654 lines
155 KiB
Text
654 lines
155 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK84551">
|
|
<meta name="ncbi_domain" content="gene">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK84551/?report=reader">
|
|
<meta name="ncbi_pagename" content="Primary Carnitine Deficiency - GeneReviews® - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Primary Carnitine Deficiency - GeneReviews® - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/gene/microcephaly/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/gene/pcd/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/gene/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="GeneReviews® [Internet]">
|
|
<meta name="citation_title" content="Primary Carnitine Deficiency">
|
|
<meta name="citation_publisher" content="University of Washington, Seattle">
|
|
<meta name="citation_date" content="2024/12/05">
|
|
<meta name="citation_author" content="Ayman W El-Hattab">
|
|
<meta name="citation_author" content="Mohammed Almannai">
|
|
<meta name="citation_pmid" content="22420015">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK84551/">
|
|
<meta name="citation_keywords" content="Carnitine Deficiency">
|
|
<meta name="citation_keywords" content="Carnitine Transport Defect (CTD)">
|
|
<meta name="citation_keywords" content="Carnitine Uptake Defect (CUD)">
|
|
<meta name="citation_keywords" content="Systemic Primary Carnitine Deficiency">
|
|
<meta name="citation_keywords" content="Carnitine Deficiency">
|
|
<meta name="citation_keywords" content="Carnitine Transport Defect (CTD)">
|
|
<meta name="citation_keywords" content="Carnitine Uptake Defect (CUD)">
|
|
<meta name="citation_keywords" content="Systemic Primary Carnitine Deficiency">
|
|
<meta name="citation_keywords" content="Organic cation/carnitine transporter 2">
|
|
<meta name="citation_keywords" content="SLC22A5">
|
|
<meta name="citation_keywords" content="Primary Carnitine Deficiency">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Primary Carnitine Deficiency">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="University of Washington, Seattle">
|
|
<meta name="DC.Contributor" content="Ayman W El-Hattab">
|
|
<meta name="DC.Contributor" content="Mohammed Almannai">
|
|
<meta name="DC.Date" content="2024/12/05">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK84551/">
|
|
<meta name="description" content="Primary carnitine deficiency (PCD) is a disorder of the carnitine cycle that results in defective fatty acid oxidation. If untreated, it encompasses a broad clinical spectrum including: (1) metabolic decompensation in infancy typically presenting between age three months and two years with episodes of hypoketotic hypoglycemia, poor feeding, irritability, lethargy, hepatomegaly, elevated liver transaminases, and hyperammonemia triggered by fasting or common illnesses such as upper respiratory tract infection or gastroenteritis; (2) childhood myopathy involving heart and skeletal muscle with onset between age two and four years; (3) pregnancy-related decreased stamina or exacerbation of cardiac arrhythmia; (4) fatigability in adulthood; and (5) absence of symptoms. The latter two categories often include mothers diagnosed with PCD after newborn screening has identified low carnitine levels in their infants.">
|
|
<meta name="og:title" content="Primary Carnitine Deficiency">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Primary carnitine deficiency (PCD) is a disorder of the carnitine cycle that results in defective fatty acid oxidation. If untreated, it encompasses a broad clinical spectrum including: (1) metabolic decompensation in infancy typically presenting between age three months and two years with episodes of hypoketotic hypoglycemia, poor feeding, irritability, lethargy, hepatomegaly, elevated liver transaminases, and hyperammonemia triggered by fasting or common illnesses such as upper respiratory tract infection or gastroenteritis; (2) childhood myopathy involving heart and skeletal muscle with onset between age two and four years; (3) pregnancy-related decreased stamina or exacerbation of cardiac arrhythmia; (4) fatigability in adulthood; and (5) absence of symptoms. The latter two categories often include mothers diagnosed with PCD after newborn screening has identified low carnitine levels in their infants.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK84551/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/gene/cdsp/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK84551/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8EBCF07C89AC4100000000002E0025.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK84551/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/gene/microcephaly/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Primary Carnitine Deficiency</div><div class="j">GeneReviews® [Internet]</div></div><div class="tail"><a href="/books/n/gene/pcd/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK84551/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK84551/&text=Primary%20Carnitine%20Deficiency"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/gene/?report=reader">Title Information</a><a href="/books/n/gene/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK84551/?report=classic">Switch to classic view</a><a href="/books/NBK84551/pdf/Bookshelf_NBK84551.pdf">PDF (530K)</a><a href="/books/NBK84551/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK84551%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8EBCF07C89AC4100000000002E0025.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK84551_"><span class="title" itemprop="name">Primary Carnitine Deficiency</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Carnitine Deficiency, Carnitine Transport Defect (CTD), Carnitine Uptake Defect (CUD), Systemic Primary Carnitine Deficiency</div><p class="contribs">El-Hattab AW, Almannai M.</p><p class="fm-aai"><a href="#_NBK84551_pubdet_">Publication Details</a></p><p><em>Estimated reading time: 27 minutes</em></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="cdsp.Summary" itemprop="description"><h2 id="_cdsp_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Primary carnitine deficiency (PCD) is a disorder of the carnitine cycle that results in defective fatty acid oxidation. If untreated, it encompasses a broad clinical spectrum including: (1) metabolic decompensation in infancy typically presenting between age three months and two years with episodes of hypoketotic hypoglycemia, poor feeding, irritability, lethargy, hepatomegaly, elevated liver transaminases, and hyperammonemia triggered by fasting or common illnesses such as upper respiratory tract infection or gastroenteritis; (2) childhood myopathy involving heart and skeletal muscle with onset between age two and four years; (3) pregnancy-related decreased stamina or exacerbation of cardiac arrhythmia; (4) fatigability in adulthood; and (5) absence of symptoms. The latter two categories often include mothers diagnosed with PCD after newborn screening has identified low carnitine levels in their infants.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of PCD is established in a proband with consistent biochemical analyte findings and/or suggestive clinical and laboratory features by identification of biallelic pathogenic variants in <i>SLC22A5</i> on molecular genetic testing. In individuals with suspected PCD and negative molecular testing, a carnitine transport assay using cultured skin fibroblasts may be available.</p></div><div><h4 class="inline">Management.</h4><p><i>Targeted therapy:</i> Metabolic decompensation and skeletal and cardiac muscle function improve with 100-200 mg/kg/day oral levocarnitine if it is started before irreversible organ damage occurs.</p><p><i>Supportive care:</i> Routine treatment includes preventing hypoglycemia with frequent feeding and avoidance of prolonged fasting; notifying designated metabolic center in advance of scheduled surgical or medical procedures; hospitalization for intravenous glucose administration for individuals who are required to fast for a procedure or who cannot tolerate oral intake due to illness such as gastroenteritis; implementing transitional care plan prior to adulthood. Emergency outpatient treatment includes levocarnitine and carbohydrate supplementation, antipyretics for fever, and antiemetics for occasional vomiting. Acute inpatient treatment includes high-calorie fluids, insulin as needed, intravenous or oral levocarnitine (100-200 mg/kg/day), evaluation of muscle and liver involvement by measuring serum creatine kinase concentration and liver transaminases, and evaluation by cardiologist with EKG and echocardiogram for cardiomyopathy.</p><p><i>Surveillance:</i> Monitor plasma carnitine concentration frequently until levels reach normal range; once levels reach normal range, measure three times a year during infancy and early childhood, twice a year in older children, and annually in adults. Assess growth and development at each visit throughout childhood. Neuropsychological testing and quality of life assessment as needed. EKG and echocardiogram annually during childhood and less frequently in adulthood.</p><p><i>Agents/circumstances to avoid:</i> Fasting longer than age-appropriate periods; catabolic illness; inadequate calorie provision during other stressors.</p><p><i>Evaluation of relatives at risk:</i> Evaluation of all sibs of any age by molecular genetic testing if the <i>SLC22A5</i> pathogenic variants in the family are known or measurement of plasma-free carnitine concentration to identify as early as possible those who would benefit from institution of treatment and preventive measures.</p><p><i>Pregnancy management:</i> Pregnant women with PCD require close monitoring of plasma carnitine levels and increased carnitine supplementation as needed to maintain plasma carnitine levels in the normal range.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>PCD is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for an <i>SLC22A5</i> pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the <i>SLC22A5</i> pathogenic variants have been identified in an affected family member, molecular genetic carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible.</p></div></div><div id="cdsp.Diagnosis"><h2 id="_cdsp_Diagnosis_">Diagnosis</h2><div id="cdsp.Suggestive_Findings"><h3>Suggestive Findings</h3><p>A diagnosis of primary carnitine deficiency (PCD) may be suspected due to an abnormal newborn screening result prior to onset of suggestive findings (see <a href="#cdsp.Scenario_1_Abnormal_Newborn_Screeni">Scenario 1</a>) or may be considered because of symptoms of PCD (see <a href="#cdsp.Scenario_2_Symptomatic_Individual">Scenario 2</a>).</p><div id="cdsp.Scenario_1_Abnormal_Newborn_Screeni"><h4>Scenario 1: Abnormal Newborn Screening (NBS) Result</h4><p>NBS for PCD is primarily based on use of dried blood spots collected between 24 hours and 72 hours after birth to quantify free carnitine (C0) concentration by tandem mass spectrometry. (For information on NBS by state in the United States, see <a href="https://newbornscreening.hrsa.gov/your-state" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">www.newbornscreening.hrsa.gov</a>.) Low concentration of free carnitine can identify (1) an infant with PCD, (2) a mother with PCD, or (3) both. NBS can identify a mother with PCD because transfer of carnitine across the placenta from an affected mother to her fetus results in a low plasma carnitine concentration in her newborn. Thus, an infant who does not have PCD but is born to a mother who has PCD can have low plasma carnitine concentrations shortly after birth, resulting in a false positive NBS result [<a class="bibr" href="#cdsp.REF.onuki.2023.1341" rid="cdsp.REF.onuki.2023.1341">Onuki et al 2023</a>, <a class="bibr" href="#cdsp.REF.van_den_heuvel.2023.134" rid="cdsp.REF.van_den_heuvel.2023.134">van den Heuvel et al 2023</a>].</p><p>Note: (1) NBS for PCD has low positive predictive value (e.g., 4.7% in California [<a class="bibr" href="#cdsp.REF.gallant.2017.76" rid="cdsp.REF.gallant.2017.76">Gallant et al 2017</a>]). There are many factors that may affect NBS for PCD, including maternal carnitine deficiency, prematurity, pivalic acid-containing antibiotics, and some other inborn errors of metabolism. At least one country (New Zealand) has discontinued NBS for this disorder because of its very low sensitivity and positive predictive value [<a class="bibr" href="#cdsp.REF.wilson.2019.86" rid="cdsp.REF.wilson.2019.86">Wilson et al 2019</a>]. (2) In the US, most NBS laboratories determine their own cutoff levels for test results that are considered to be out of range and require further laboratory testing because out-of-range NBS results individually are not entirely specific to PCD.</p><p>Positive NBS results (i.e., low blood concentrations of free carnitine) require evaluation of the newborn and mother as soon as possible and no later than three days after birth.</p><ul><li class="half_rhythm"><div>See <a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_test/?report=objectonly" target="object" rid-ob="figobcdspTprimarycarnitinedeficiencytest">Table 1</a> and <a href="#cdsp.Establishing_the_Diagnosis">Establishing the Diagnosis</a> on how to make an analyte diagnosis or confirm a diagnosis molecularly.</div></li><li class="half_rhythm"><div>For recommendations on presumptive treatment of affected newborns while awaiting diagnosis confirmation to prevent irreversible neurocognitive impairment, consult a metabolic specialist to discuss immediate treatment for PCD with oral levocarnitine supplementation and other recommended care.</div></li><li class="half_rhythm"><div>If a metabolic specialist is not available, begin treatment for PCD with oral levocarnitine supplementation (typically 100-200 mg/kg/day, divided in three doses; see <a href="#cdsp.Management">Management</a>) to prevent metabolic decompensation.</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcdspTprimarycarnitinedeficiencytest"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_test/?report=objectonly" target="object" title="Table 1. " class="img_link icnblk_img" rid-ob="figobcdspTprimarycarnitinedeficiencytest"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cdsp.T.primary_carnitine_deficiency_test"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_test/?report=objectonly" target="object" rid-ob="figobcdspTprimarycarnitinedeficiencytest">Table 1. </a></h4><p class="float-caption no_bottom_margin">Primary Carnitine Deficiency: Testing Recommended at the Time of Diagnosis of Low Carnitine Blood Levels via NBS </p></div></div></div><div id="cdsp.Scenario_2_Symptomatic_Individual"><h4>Scenario 2: Symptomatic Individual</h4><p>A symptomatic individual can have either (1) typical findings associated with later-onset PCD or (2) untreated infantile-onset PCD resulting from any of the following: NBS not performed, false negative NBS result, clinical findings prior to receiving NBS result, or caregivers not adherent to recommended treatment after a positive NBS result. PCD <b>should be considered</b> in probands with the following clinical and laboratory findings and family history.</p><p>
|
|
<b>Clinical and supportive laboratory findings</b>
|
|
</p><ul><li class="half_rhythm"><div>Episodes of hypoketotic hypoglycemia that may be associated with hepatomegaly, elevated liver transaminases, abnormal liver function tests, and hyperammonemia in infants</div></li><li class="half_rhythm"><div>Skeletal myopathy and/or elevated serum concentration of creatine kinase in children</div></li><li class="half_rhythm"><div>Cardiomyopathy in children</div></li><li class="half_rhythm"><div>Unexplained fatigability in adults</div></li><li class="half_rhythm"><div>Decreased plasma carnitine concentrations without an identified cause in individuals of any age</div></li></ul><p><b>Family history</b> is consistent with autosomal recessive inheritance (e.g., affected sibs and/or parental consanguinity). Absence of a known family history does not preclude the diagnosis.</p></div></div><div id="cdsp.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><div id="cdsp.Analyte_Diagnosis"><h4>Analyte Diagnosis</h4><p>The biochemical diagnosis (in limited instances) <b>is established</b> in a proband by identification of extremely reduced plasma free, acylated, and total (i.e., the sum of free and acylated) carnitine concentrations (i.e., <10% of controls).</p></div><div id="cdsp.Molecular_Genetic_Diagnosis"><h4>Molecular Genetic Diagnosis</h4><p>The molecular genetic diagnosis of PCD <b>is established</b> in a proband with consistent analyte findings and/or suggestive clinical and laboratory features by identification of biallelic pathogenic (or likely pathogenic) variants in <i>SLC22A5</i> on molecular genetic testing (see <a href="/books/NBK84551/table/cdsp.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-ob="figobcdspTmoleculargenetictestingusedin">Table 2</a>).</p><p>Note: (1) Per ACMG/AMP variant interpretation guidelines, the terms "pathogenic variant" and "likely pathogenic variant" are synonymous in a clinical setting, meaning that both are considered diagnostic and can be used for clinical decision making [<a class="bibr" href="#cdsp.REF.richards.2015.405" rid="cdsp.REF.richards.2015.405">Richards et al 2015</a>]. Reference to "pathogenic variants" in this <i>GeneReview</i> is understood to include likely pathogenic variants. (2) Identification of biallelic <i>SLC22A5</i> variants of uncertain significance (or of one known <i>SLC22A5</i> pathogenic variant and one <i>SLC22A5</i> variant of uncertain significance) does not establish or rule out the diagnosis.</p><p>Molecular genetic testing approaches can include a combination of <b>gene-targeted testing</b> (single gene testing, multigene panel) and <b>comprehensive</b>
|
|
<b>genomic testing</b> (exome sequencing, genome sequencing). Gene-targeted testing requires that the clinician determine which gene(s) are likely involved (see <a href="#cdsp.Option_1">Option 1</a>), whereas comprehensive genomic testing does not (see <a href="#cdsp.Option_2">Option 2</a>).</p><div id="cdsp.Option_1"><h5>
|
|
<b>Option 1</b>
|
|
</h5><p>When NBS results and other laboratory findings suggest the diagnosis of PCD, molecular genetic testing approaches can include <b>single-gene testing</b> or use of a <b>multigene panel testing</b>.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-gene testing.</b> Sequence analysis of <i>SLC22A5</i> is performed first to detect missense, nonsense, and splice site variants and small intragenic deletions/insertions. Note: Depending on the sequencing method used, single-exon, multiexon, or whole-gene deletions/duplications may not be detected. If only one or no variant is detected by the sequencing method used, the next step is to perform gene-targeted deletion/duplication analysis to detect exon and whole-gene deletions or duplications; at least one large deletion has been identified [<a class="bibr" href="#cdsp.REF.li.2010.e1632" rid="cdsp.REF.li.2010.e1632">Li et al 2010</a>].</div><div class="half_rhythm">In individuals with suspected PCD and negative molecular testing, a carnitine transport assay using cultured skin fibroblasts may be available to confirm the diagnosis [<a class="bibr" href="#cdsp.REF.crefcoeur.2023.1177" rid="cdsp.REF.crefcoeur.2023.1177">Crefcoeur et al 2023</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>An inborn errors of metabolism or metabolic myopathy multigene panel</b> that includes <i>SLC22A5</i> and other genes of interest (see <a href="#cdsp.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/?report=reader#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/?report=reader#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul></div><div id="cdsp.Option_2"><h5>
|
|
<b>Option 2</b>
|
|
</h5><p><b>Exome or genome sequencing</b> can be used. Ordering a rapid turnaround time exome or genome sequencing is necessary when newborns or infants are critically ill. To date, the majority of <i>SLC22A5</i> pathogenic variants reported (e.g., missense, nonsense) are within the coding region and are likely to be identified on exome sequencing [<a class="bibr" href="#cdsp.REF.frigeni.2017.1684" rid="cdsp.REF.frigeni.2017.1684">Frigeni et al 2017</a>, <a class="bibr" href="#cdsp.REF.chen.2021.e1583" rid="cdsp.REF.chen.2021.e1583">Chen et al 2021</a>, <a class="bibr" href="#cdsp.REF.lin.2021.503" rid="cdsp.REF.lin.2021.503">Lin et al 2021</a>, <a class="bibr" href="#cdsp.REF.koleske.2022.e2210247119" rid="cdsp.REF.koleske.2022.e2210247119">Koleske et al 2022</a>].</p><p>For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/?report=reader#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/?report=reader#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcdspTmoleculargenetictestingusedin"><a href="/books/NBK84551/table/cdsp.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" title="Table 2. " class="img_link icnblk_img" rid-ob="figobcdspTmoleculargenetictestingusedin"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cdsp.T.molecular_genetic_testing_used_in"><a href="/books/NBK84551/table/cdsp.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-ob="figobcdspTmoleculargenetictestingusedin">Table 2. </a></h4><p class="float-caption no_bottom_margin">Molecular Genetic Testing Used in Primary Carnitine Deficiency </p></div></div></div></div></div></div><div id="cdsp.Clinical_Characteristics"><h2 id="_cdsp_Clinical_Characteristics_">Clinical Characteristics</h2><div id="cdsp.Clinical_Description"><h3>Clinical Description</h3><p>The clinical manifestations of primary carnitine deficiency (PCD) can vary widely with respect to age of onset, organ involvement, and severity. The broad clinical spectrum ranges from metabolic decompensation in infancy to cardiomyopathy in childhood, fatigability in adulthood, and absence of clinical manifestations. PCD has typically been associated with an infantile metabolic presentation that usually presents before age two years in about half of untreated affected individuals. The remaining half have a childhood myopathic presentation that typically presents between ages two and four years with dilated cardiomyopathy, hypotonia, muscle weakness, and elevated creatine kinase (CK). However, adults with PCD and mild or no manifestations are likely underdiagnosed, making it difficult to determine the relative proportion of these presentations [<a class="bibr" href="#cdsp.REF.elhattab.2015.107" rid="cdsp.REF.elhattab.2015.107">El-Hattab & Scaglia 2015</a>, <a class="bibr" href="#cdsp.REF.longo.2016.2422" rid="cdsp.REF.longo.2016.2422">Longo et al 2016</a>].</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcdspTprimarycarnitinedeficiencysele"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_sele/?report=objectonly" target="object" title="Table 3. " class="img_link icnblk_img" rid-ob="figobcdspTprimarycarnitinedeficiencysele"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cdsp.T.primary_carnitine_deficiency_sele"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_sele/?report=objectonly" target="object" rid-ob="figobcdspTprimarycarnitinedeficiencysele">Table 3. </a></h4><p class="float-caption no_bottom_margin">Primary Carnitine Deficiency: Select Features </p></div></div><div id="cdsp.Infantile_Early_Diagnosis_and_Treat"><h4>Infantile Early Diagnosis and Treatment</h4><p>Infants diagnosed with newborn screening (NBS) and treated early are usually asymptomatic, as manifestations can be prevented by maintaining normal plasma carnitine levels.</p></div><div id="cdsp.Infantile_Metabolic_Hepatic_Present"><h4>Infantile Metabolic (Hepatic) Presentation</h4><p><b>Metabolic decompensation.</b> Affected children can present between age three months and two years with episodes of metabolic decompensation triggered by fasting or common illnesses such as upper respiratory tract infection or gastroenteritis. These episodes are characterized clinically by poor feeding, irritability, lethargy, and hepatomegaly. Laboratory evaluations usually reveal hypoketotic hypoglycemia (hypoglycemia with minimal or no ketones in urine), hyperammonemia, and elevated liver transaminases. If affected children are not treated with intravenous dextrose infusion during episodes of metabolic decompensation (see <a href="#cdsp.Management">Management</a>), they may develop coma and die [<a class="bibr" href="#cdsp.REF.longo.2006.77" rid="cdsp.REF.longo.2006.77">Longo et al 2006</a>, <a class="bibr" href="#cdsp.REF.elhattab.2015.107" rid="cdsp.REF.elhattab.2015.107">El-Hattab & Scaglia 2015</a>].</p><p><b>Myopathic manifestations.</b> Older children with the infantile presentation may also develop myopathic manifestations including elevated CK, cardiomyopathy, and skeletal muscle weakness [<a class="bibr" href="#cdsp.REF.longo.2006.77" rid="cdsp.REF.longo.2006.77">Longo et al 2006</a>, <a class="bibr" href="#cdsp.REF.elhattab.2015.107" rid="cdsp.REF.elhattab.2015.107">El-Hattab & Scaglia 2015</a>].</p><p><b>Neurologic manifestations.</b> Muscular hypotonia, irritability, rigors, dystonia, and reduced consciousness secondary to metabolic decompensation are possible complications of PCD. Long-term clinical effects are related to the number and severity of metabolic decompensation episodes.</p><p><b>Growth.</b> Growth (linear growth, head circumference, and weight) can be negatively impacted if untreated.</p></div><div id="cdsp.Childhood_Myopathic_Cardiac_Present"><h4>Childhood Myopathic (Cardiac) Presentation</h4><p><b>Skeletal myopathy.</b> Myopathic manifestations include hypotonia, skeletal muscle weakness, and elevated serum CK.</p><p><b>Cardiomyopathy.</b> Dilated cardiomyopathy is often present. PCD is associated with shortening of the QT interval and can result in arrhythmia [<a class="bibr" href="#cdsp.REF.lodewyckx.2023.107733" rid="cdsp.REF.lodewyckx.2023.107733">Lodewyckx et al 2023</a>]. Death from cardiac failure can occur before the diagnosis is established, indicating that this presentation can be fatal if not treated.</p><p><b>Metabolic decompensations</b> also occur in childhood-onset PCD, with hypotonia, weakness, hypoketotic hypoglycemia, hyperammonemia, increased liver transaminases, and increased CK.</p><p><b>Growth.</b> Growth (linear growth, head circumference, and weight) can be negatively impacted if untreated.</p></div><div id="cdsp.Adulthood_Presentation"><h4>Adulthood Presentation</h4><p>Adults can present with life-threatening symptoms after being asymptomatic [<a class="bibr" href="#cdsp.REF.crefcoeur.2022.386" rid="cdsp.REF.crefcoeur.2022.386">Crefcoeur et al 2022</a>]. Cardiac arrythmias and sudden death can occur. Cardiomyopathy in individuals with PCD responds poorly to standard therapy, and without accurate diagnosis and carnitine supplementation, it can be fatal. PCD can result in shortening of the QT interval, inducing severe arrhythmia [<a class="bibr" href="#cdsp.REF.lodewyckx.2023.107733" rid="cdsp.REF.lodewyckx.2023.107733">Lodewyckx et al 2023</a>].</p><p>One study from the Faroe Islands estimated an odds ratio (OR) of 54.3 for the association between sudden death and untreated PCD [<a class="bibr" href="#cdsp.REF.rasmussen.2014.215" rid="cdsp.REF.rasmussen.2014.215">Rasmussen et al 2014</a>]. This indicates the importance of screening at-risk individuals and adherence to treatment with levocarnitine supplementation to prevent the possibility of decompensation during intercurrent illness or stress or even sudden death.</p><p>Several women have been diagnosed with PCD after NBS identified low carnitine levels in their infants. About half of those women reported fatigability, whereas the other half were asymptomatic. One woman had dilated cardiomyopathy, and another had arrhythmias [<a class="bibr" href="#cdsp.REF.schimmenti.2007.441" rid="cdsp.REF.schimmenti.2007.441">Schimmenti et al 2007</a>, <a class="bibr" href="#cdsp.REF.elhattab.2010.19" rid="cdsp.REF.elhattab.2010.19">El-Hattab et al 2010</a>, <a class="bibr" href="#cdsp.REF.lee.2010.46" rid="cdsp.REF.lee.2010.46">Lee et al 2010</a>].</p></div></div><div id="cdsp.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No genotype-phenotype correlations have been identified.</p><p>Nonsense and frameshift variants in <i>SLC22A5</i> are more prevalent in symptomatic individuals. Missense variants are more prevalent in asymptomatic individuals [<a class="bibr" href="#cdsp.REF.rose.2012.118" rid="cdsp.REF.rose.2012.118">Rose et al 2012</a>, <a class="bibr" href="#cdsp.REF.ji.2023.1304458" rid="cdsp.REF.ji.2023.1304458">Ji et al 2023</a>].</p></div><div id="cdsp.Prevalence"><h3>Prevalence</h3><p>PCD is very common in the Faroe Islands, where the reported prevalence is 1:300 [<a class="bibr" href="#cdsp.REF.rasmussen.2014.215" rid="cdsp.REF.rasmussen.2014.215">Rasmussen et al 2014</a>]. The most prevalent pathogenic founder variant in this population is c.95A>G (p.Asn32Ser) (see <a href="/books/NBK84551/table/cdsp.T.slc22a5_pathogenic_variants_refer/?report=objectonly" target="object" rid-ob="figobcdspTslc22a5pathogenicvariantsrefer">Table 11</a>).</p><p>NBS data estimated the incidence of PCD to be 1:348,333 in Australia and New Zealand, 1:121,609 in North America, 1:127,912 in Europe (excluding Denmark, Greenland, and the Faroe Islands) and 1:50,386 in Asia [<a class="bibr" href="#cdsp.REF.lef_vre.2023.6" rid="cdsp.REF.lef_vre.2023.6">Lefèvre et al 2023</a>]. Some studies have suggested a higher prevalence in the Chinese population of 1:17,456 [<a class="bibr" href="#cdsp.REF.ji.2023.1304458" rid="cdsp.REF.ji.2023.1304458">Ji et al 2023</a>].</p></div></div><div id="cdsp.Genetically_Related_Allelic_Disorde"><h2 id="_cdsp_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with germline pathogenic variants in <i>SLC22A5.</i></p></div><div id="cdsp.Differential_Diagnosis"><h2 id="_cdsp_Differential_Diagnosis_">Differential Diagnosis</h2><p>Primary carnitine deficiency (PCD) needs to be differentiated from secondary carnitine deficiency associated with other inherited metabolic disorders, including organic acidemias and fatty acid oxidation defects (see <a href="/books/NBK84551/table/cdsp.T.selected_autosomal_recessive_diso/?report=objectonly" target="object" rid-ob="figobcdspTselectedautosomalrecessivediso">Table 4</a>), and acquired conditions [<a class="bibr" href="#cdsp.REF.longo.2016.2422" rid="cdsp.REF.longo.2016.2422">Longo et al 2016</a>].</p><p><b>Genetic disorders.</b> Free and total carnitines, a plasma acylcarnitine profile, and urine organic acid analysis can be useful in differentiating fatty acid oxidation disorders and organic acidemias from PCD.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcdspTselectedautosomalrecessivediso"><a href="/books/NBK84551/table/cdsp.T.selected_autosomal_recessive_diso/?report=objectonly" target="object" title="Table 4. " class="img_link icnblk_img" rid-ob="figobcdspTselectedautosomalrecessivediso"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cdsp.T.selected_autosomal_recessive_diso"><a href="/books/NBK84551/table/cdsp.T.selected_autosomal_recessive_diso/?report=objectonly" target="object" rid-ob="figobcdspTselectedautosomalrecessivediso">Table 4. </a></h4><p class="float-caption no_bottom_margin">Selected Autosomal Recessive Disorders Associated with Secondary Carnitine Deficiency in the Differential Diagnosis of Primary Carnitine Deficiency </p></div></div><p>
|
|
<b>Acquired conditions</b>
|
|
</p><ul><li class="half_rhythm"><div>Pharmacologic therapy (e.g., valproate, cyclosporine, pivampicillin)</div></li><li class="half_rhythm"><div>Malnutrition</div></li><li class="half_rhythm"><div>Hemodialysis and renal tubular dysfunction (e.g., renal Fanconi syndrome)</div></li><li class="half_rhythm"><div>Prematurity. Premature neonates may have mild reduction in plasma carnitine concentrations due to a lack of carnitine placental transfer in the third trimester and decreased tissue stores. Moreover, immature renal tubular function in premature neonates could lead to increased renal carnitine elimination [<a class="bibr" href="#cdsp.REF.li.2010.e1632" rid="cdsp.REF.li.2010.e1632">Li et al 2010</a>, <a class="bibr" href="#cdsp.REF.clark.2014.e37" rid="cdsp.REF.clark.2014.e37">Clark et al 2014</a>].</div></li></ul></div><div id="cdsp.Management"><h2 id="_cdsp_Management_">Management</h2><p>No clinical practice guidelines for primary carnitine deficiency (PCD) have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder.</p><div id="cdsp.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with PCD, the evaluations summarized in <a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_reco/?report=objectonly" target="object" rid-ob="figobcdspTprimarycarnitinedeficiencyreco">Table 5</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcdspTprimarycarnitinedeficiencyreco"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_reco/?report=objectonly" target="object" title="Table 5. " class="img_link icnblk_img" rid-ob="figobcdspTprimarycarnitinedeficiencyreco"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cdsp.T.primary_carnitine_deficiency_reco"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_reco/?report=objectonly" target="object" rid-ob="figobcdspTprimarycarnitinedeficiencyreco">Table 5. </a></h4><p class="float-caption no_bottom_margin">Primary Carnitine Deficiency: Recommended Evaluations Following Initial Diagnosis </p></div></div></div><div id="cdsp.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="cdsp.Targeted_Therapy"><h4>Targeted Therapy</h4><p>
|
|
<i>In GeneReviews, a targeted therapy is one that addresses the specific underlying mechanism of disease causation (regardless of whether the therapy is significantly efficacious for one or more manifestation of the genetic condition); would otherwise not be considered without knowledge of the underlying genetic cause of the condition; or could lead to a cure</i>. —ED</p><p>Targeted therapy for PCD involves oral carnitine supplementation to prevent carnitine deficiency (see <a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_targ/?report=objectonly" target="object" rid-ob="figobcdspTprimarycarnitinedeficiencytarg">Table 6</a>).</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcdspTprimarycarnitinedeficiencytarg"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_targ/?report=objectonly" target="object" title="Table 6. " class="img_link icnblk_img" rid-ob="figobcdspTprimarycarnitinedeficiencytarg"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cdsp.T.primary_carnitine_deficiency_targ"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_targ/?report=objectonly" target="object" rid-ob="figobcdspTprimarycarnitinedeficiencytarg">Table 6. </a></h4><p class="float-caption no_bottom_margin">Primary Carnitine Deficiency: Targeted Therapy </p></div></div><p>Oral levocarnitine supplementation in infants with PCD identified through newborn screening (NBS) results in slow normalization of the plasma carnitine concentration.</p><p>Metabolic decompensation and skeletal and cardiac muscle function improve with levocarnitine supplementation. Individuals with PCD respond well if oral levocarnitine supplementation is started before irreversible organ damage occurs.</p></div><div id="cdsp.Supportive_Care"><h4>Supportive Care</h4><p>One of the most important components of preventing carnitine deficiency is education of parents and caregivers such that diligent observation and management can be administered expediently in the setting of intercurrent illness or other catabolic stressors (see <a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_rout/?report=objectonly" target="object" rid-ob="figobcdspTprimarycarnitinedeficiencyrout">Table 7</a> and <a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_emer/?report=objectonly" target="object" rid-ob="figobcdspTprimarycarnitinedeficiencyemer">Table 8</a>). Essential information including written treatment protocols should be provided before inpatient emergency treatment might be necessary.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcdspTprimarycarnitinedeficiencyrout"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_rout/?report=objectonly" target="object" title="Table 7. " class="img_link icnblk_img" rid-ob="figobcdspTprimarycarnitinedeficiencyrout"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cdsp.T.primary_carnitine_deficiency_rout"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_rout/?report=objectonly" target="object" rid-ob="figobcdspTprimarycarnitinedeficiencyrout">Table 7. </a></h4><p class="float-caption no_bottom_margin">Primary Carnitine Deficiency: Routine Outpatient Treatment of Manifestations </p></div></div><p><b>Emergency outpatient treatment.</b> Parents or local hospitals should immediately inform the specialized metabolic center when the following occurs:</p><ul><li class="half_rhythm"><div>Fever</div></li><li class="half_rhythm"><div>Vomiting/diarrhea or other manifestations of intercurrent illness</div></li><li class="half_rhythm"><div>New neurologic findings</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcdspTprimarycarnitinedeficiencyemer"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_emer/?report=objectonly" target="object" title="Table 8. " class="img_link icnblk_img" rid-ob="figobcdspTprimarycarnitinedeficiencyemer"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cdsp.T.primary_carnitine_deficiency_emer"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_emer/?report=objectonly" target="object" rid-ob="figobcdspTprimarycarnitinedeficiencyemer">Table 8. </a></h4><p class="float-caption no_bottom_margin">Primary Carnitine Deficiency: Emergency Outpatient Treatment </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcdspTprimarycarnitinedeficiencyacut"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_acut/?report=objectonly" target="object" title="Table 9. " class="img_link icnblk_img" rid-ob="figobcdspTprimarycarnitinedeficiencyacut"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cdsp.T.primary_carnitine_deficiency_acut"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_acut/?report=objectonly" target="object" rid-ob="figobcdspTprimarycarnitinedeficiencyacut">Table 9. </a></h4><p class="float-caption no_bottom_margin">Primary Carnitine Deficiency: Acute Inpatient Treatment </p></div></div></div></div><div id="cdsp.Surveillance"><h3>Surveillance</h3><p>In addition to regular evaluations by a metabolic specialist and metabolic dietician, the evaluations summarized in <a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_reco_1/?report=objectonly" target="object" rid-ob="figobcdspTprimarycarnitinedeficiencyreco1">Table 10</a> are recommended to monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcdspTprimarycarnitinedeficiencyreco1"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_reco_1/?report=objectonly" target="object" title="Table 10. " class="img_link icnblk_img" rid-ob="figobcdspTprimarycarnitinedeficiencyreco1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cdsp.T.primary_carnitine_deficiency_reco_1"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_reco_1/?report=objectonly" target="object" rid-ob="figobcdspTprimarycarnitinedeficiencyreco1">Table 10. </a></h4><p class="float-caption no_bottom_margin">Primary Carnitine Deficiency: Recommended Surveillance </p></div></div></div><div id="cdsp.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Avoid the following:</p><ul><li class="half_rhythm"><div>Prolonged fasting beyond age-appropriate periods</div></li><li class="half_rhythm"><div>Catabolic illness (using measures to avoid intercurrent infection, such as being up to date on vaccinations with anticipation of likelihood of febrile illness post vaccination, wearing a mask in crowded environments, considering alternatives to daycare, recognizing symptoms early)</div></li><li class="half_rhythm"><div>Inadequate caloric provision during other stressors, especially when fasting is involved (surgery or procedure requiring fasting/anesthesia)</div></li></ul></div><div id="cdsp.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p><b>Testing of all sibs of any age</b> at increased risk of PCD is warranted to identify as early as possible those who would benefit from institution of treatment and preventive measures.</p><ul><li class="half_rhythm"><div>If the <i>SLC22A5</i> pathogenic variants in the family are known, molecular genetic testing can be used to clarify the genetic status of at-risk sibs.</div></li><li class="half_rhythm"><div>If the pathogenic variants in the family are not known, measure plasma free carnitine concentrations. If the free carnitine concentrations are low, further evaluation for PCD is available using carnitine uptake studies in cultured skin fibroblasts [<a class="bibr" href="#cdsp.REF.crefcoeur.2023.1177" rid="cdsp.REF.crefcoeur.2023.1177">Crefcoeur et al 2023</a>].</div></li></ul><p><b>For at-risk newborn sibs</b>
|
|
<b>when prenatal testing was not performed.</b> In parallel with NBS, perform either molecular genetic testing for the familial <i>SLC22A5</i> pathogenic variants or plasma carnitines (free and total).</p><p>See <a href="#cdsp.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for genetic counseling purposes.</p></div><div id="cdsp.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Pregnancy is a metabolically challenging state for women with PCD because energy consumption significantly increases. In addition, plasma carnitine concentrations are physiologically lower in women with PCD during pregnancy than those of non-pregnant controls. Women with PCD can have decreased stamina or worsening of cardiac arrhythmia during pregnancy, suggesting that PCD may manifest or exacerbate during pregnancy [<a class="bibr" href="#cdsp.REF.schimmenti.2007.441" rid="cdsp.REF.schimmenti.2007.441">Schimmenti et al 2007</a>, <a class="bibr" href="#cdsp.REF.elhattab.2010.19" rid="cdsp.REF.elhattab.2010.19">El-Hattab et al 2010</a>]. Therefore, it is recommended that all pregnant women with PCD, including those who are asymptomatic, have close monitoring of plasma carnitine concentrations, followed by increased carnitine supplementation as needed to maintain normal plasma carnitine concentrations.</p></div><div id="cdsp.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">ClinicalTrials.gov</a> in the US and <a href="https://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="cdsp.Genetic_Counseling"><h2 id="_cdsp_Genetic_Counseling_">Genetic Counseling</h2><p>
|
|
<i>Genetic counseling is the process of providing individuals and families with
|
|
information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them
|
|
make informed medical and personal decisions. The following section deals with genetic
|
|
risk assessment and the use of family history and genetic testing to clarify genetic
|
|
status for family members; it is not meant to address all personal, cultural, or
|
|
ethical issues that may arise or to substitute for consultation with a genetics
|
|
professional</i>. —ED.</p><div id="cdsp.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Primary carnitine deficiency (PCD) is inherited in an autosomal recessive manner.</p></div><div id="cdsp.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p>
|
|
<b>Parents of a proband</b>
|
|
</p><ul><li class="half_rhythm"><div>The parents of an affected individual are presumed to be heterozygous for an <i>SLC22A5</i> pathogenic variant.</div></li><li class="half_rhythm"><div>If a molecular diagnosis has been established in the proband, molecular genetic testing is recommended for the parents of a proband to determine the genetic status of the parents and allow reliable recurrence risk assessment.</div></li><li class="half_rhythm"><div>Occasionally an asymptomatic parent is found to have biallelic <i>SLC22A5</i> pathogenic variants. In this event, the asymptomatic parent should be referred to a specialist center with experience in management of inherited metabolic diseases for initiation of treatment and surveillance (see <a href="#cdsp.Management">Management</a>).</div></li><li class="half_rhythm"><div>If a pathogenic variant is detected in only one parent and parental identity testing has confirmed biological maternity and paternity, it is possible that one of the pathogenic variants identified in the proband occurred as a <i>de novo</i> event in the proband or as a postzygotic <i>de novo</i> event in a mosaic parent [<a class="bibr" href="#cdsp.REF.j_nsson.2017.519" rid="cdsp.REF.j_nsson.2017.519">Jónsson et al 2017</a>]. If the proband appears to have homozygous pathogenic variants (i.e., the same two pathogenic variants), additional possibilities to consider include:</div><ul><li class="half_rhythm"><div>A single- or multiexon deletion in the proband that was not detected by sequence analysis and that resulted in the artifactual appearance of homozygosity.</div></li><li class="half_rhythm"><div>Uniparental isodisomy for the parental chromosome with the pathogenic variant that resulted in homozygosity for the pathogenic variant in the proband.</div></li></ul></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p>
|
|
<b>Sibs of a proband</b>
|
|
</p><ul><li class="half_rhythm"><div>If both parents are known to be heterozygous for an <i>SLC22A5</i> pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a proband.</b> The offspring of an individual with PCD are obligate heterozygotes (carriers) for an <i>SLC22A5</i> pathogenic variant.</p><p><b>Other family members.</b> Each sib of the proband's parents is at a 50% risk of being a carrier of an <i>SLC22A5</i> pathogenic variant.</p></div><div id="cdsp.Carrier_Detection"><h3>Carrier Detection</h3><p>Molecular genetic carrier testing for at-risk relatives requires prior identification of the <i>SLC22A5</i> pathogenic variants in the family.</p></div><div id="cdsp.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#cdsp.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p>
|
|
<b>Family planning</b>
|
|
</p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</div></li><li class="half_rhythm"><div>Carrier testing should be considered for the reproductive partners of known carriers and for the reproductive partners of individuals affected with PCD, particularly if both partners are of the same ancestry. A founder variant has been identified in the Faroe Islander population (see <a href="/books/NBK84551/table/cdsp.T.slc22a5_pathogenic_variants_refer/?report=objectonly" target="object" rid-ob="figobcdspTslc22a5pathogenicvariantsrefer">Table 11</a>).</div></li></ul><p><b>DNA banking.</b> Because it is likely that testing methodology and our understanding of genes, pathogenic mechanisms, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative pathogenic mechanism is unknown). For more information, see <a class="bibr" href="#cdsp.REF.huang.2022.389" rid="cdsp.REF.huang.2022.389">Huang et al [2022]</a>.</p></div><div id="cdsp.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p>Once the <i>SLC22A5</i> pathogenic variants have been identified in an affected family member, prenatal and preimplantation genetic testing are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal and preimplantation genetic testing. While most health care professionals would consider use of prenatal and preimplantation genetic testing to be a personal decision, discussion of these issues may be helpful.</p></div></div><div id="cdsp.Resources"><h2 id="_cdsp_Resources_">Resources</h2><p>
|
|
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
|
|
support organizations and/or registries for the benefit of individuals with this disorder
|
|
and their families. GeneReviews is not responsible for the information provided by other
|
|
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/?report=reader">here</a>.</i></p>
|
|
<ul><li class="half_rhythm"><div>
|
|
<b>MedlinePlus</b>
|
|
</div><div>
|
|
<a href="https://medlineplus.gov/genetics/condition/primary-carnitine-deficiency/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Primary carnitine deficiency</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>FOD Family Support Group (Fatty Oxidation Disorder)</b>
|
|
</div><div><b>Phone:</b> 517-381-1940</div><div><b>Email:</b> deb@fodsupport.org; fodgroup@gmail.com</div><div>
|
|
<a href="http://www.fodsupport.org" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">fodsupport.org</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>Metabolic Support UK</b>
|
|
</div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div>
|
|
<a href="https://metabolicsupportuk.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">metabolicsupportuk.org</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>Newborn Screening in Your State</b>
|
|
</div><div>Health Resources & Services Administration</div><div>
|
|
<a href="https://newbornscreening.hrsa.gov/your-state" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">newbornscreening.hrsa.gov/your-state</a>
|
|
</div></li></ul>
|
|
</div><div id="cdsp.Molecular_Genetics"><h2 id="_cdsp_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —</i>ED.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcdspmolgenTA"><a href="/books/NBK84551/table/cdsp.molgen.TA/?report=objectonly" target="object" title="Table A." class="img_link icnblk_img" rid-ob="figobcdspmolgenTA"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cdsp.molgen.TA"><a href="/books/NBK84551/table/cdsp.molgen.TA/?report=objectonly" target="object" rid-ob="figobcdspmolgenTA">Table A.</a></h4><p class="float-caption no_bottom_margin">Primary Carnitine Deficiency: Genes and Databases </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcdspmolgenTB"><a href="/books/NBK84551/table/cdsp.molgen.TB/?report=objectonly" target="object" title="Table B." class="img_link icnblk_img" rid-ob="figobcdspmolgenTB"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cdsp.molgen.TB"><a href="/books/NBK84551/table/cdsp.molgen.TB/?report=objectonly" target="object" rid-ob="figobcdspmolgenTB">Table B.</a></h4><p class="float-caption no_bottom_margin">OMIM Entries for Primary Carnitine Deficiency (View All in OMIM) </p></div></div><div id="cdsp.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>Carnitine, required for the intracellular transfer of long-chain fatty acids from the cytoplasm to the mitochondrial matrix for beta-oxidation, is transported into cells by OCTN2 (encoded by <i>SLC22A5</i>), the organic cation transporter present in the kidney, heart, and muscle and many other tissues<i>.</i> During periods of fasting, fatty acids are the predominant substrate for energy production via oxidation in the liver, cardiac muscle, and skeletal muscle. When OCTN2 is not working properly, carnitine is improperly transferred across the cell membrane, resulting in urinary carnitine wasting, low plasma carnitine concentration, and decreased intracellular carnitine accumulation. As the main function of carnitine is to transfer long-chain fatty acids from the cytoplasm into the mitochondria for beta-oxidation, carnitine deficiency results in defective fatty acid oxidation. When fat cannot be utilized glucose is consumed without regeneration via gluconeogenesis, resulting in hypoglycemia. In addition, fats released from adipose tissue accumulate in the liver, skeletal muscle, and heart result in hepatic steatosis and myopathy [<a class="bibr" href="#cdsp.REF.longo.2006.77" rid="cdsp.REF.longo.2006.77">Longo et al 2006</a>, <a class="bibr" href="#cdsp.REF.elhattab.2015.107" rid="cdsp.REF.elhattab.2015.107">El-Hattab & Scaglia 2015</a>].</p><p><b>Mechanism of disease causation</b>. Loss of function</p><p><b><i>SLC22A5</i>-specific laboratory technical considerations.</b> In one cohort of 236 individuals, a variant in the 5' untranslated region (UTR) (c.‐149G>A) was identified in 57 individuals in whom only one or no <i>SLC22A5</i> pathogenic variant in the coding region was identified [<a class="bibr" href="#cdsp.REF.ferdinandusse.2019.1899" rid="cdsp.REF.ferdinandusse.2019.1899">Ferdinandusse et al 2019</a>].</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figcdspTslc22a5pathogenicvariantsrefer"><a href="/books/NBK84551/table/cdsp.T.slc22a5_pathogenic_variants_refer/?report=objectonly" target="object" title="Table 11. " class="img_link icnblk_img" rid-ob="figobcdspTslc22a5pathogenicvariantsrefer"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="cdsp.T.slc22a5_pathogenic_variants_refer"><a href="/books/NBK84551/table/cdsp.T.slc22a5_pathogenic_variants_refer/?report=objectonly" target="object" rid-ob="figobcdspTslc22a5pathogenicvariantsrefer">Table 11. </a></h4><p class="float-caption no_bottom_margin"><i>SLC22A5</i> Pathogenic Variants Referenced in This <i>GeneReview</i> </p></div></div></div></div><div id="cdsp.Chapter_Notes"><h2 id="_cdsp_Chapter_Notes_">Chapter Notes</h2><div id="cdsp.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>5 December 2024 (gf) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 November 2016 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 June 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 March 2012 (me) Review posted live</div></li><li class="half_rhythm"><div>5 December 2011 (aeh) Original submission</div></li></ul></div></div><div id="cdsp.References"><h2 id="_cdsp_References_">References</h2><div id="cdsp.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.chen.2021.e1583">Chen
|
|
Y, Lin
|
|
Q, Zeng
|
|
Y, Qiu
|
|
X, Liu
|
|
G, Zhu
|
|
W. Gene spectrum and clinical traits of 10 patients with primary carnitine deficiency.
|
|
Mol Genet Genomic Med.
|
|
2021;9:e1583.
|
|
[<a href="/pmc/articles/PMC8077093/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8077093</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33560599" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33560599</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.clark.2014.e37">Clark
|
|
RH, Kelleher
|
|
AS, Chace
|
|
DH, Spitzer
|
|
AR. Gestational age and age at sampling influence metabolic profiles in premature infants.
|
|
Pediatrics.
|
|
2014;134:e37-46.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/24913786" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24913786</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.crefcoeur.2022.386">Crefcoeur
|
|
LL, Visser
|
|
G, Ferdinandusse
|
|
S, Wijburg
|
|
FA, Langeveld
|
|
M, Sjouke
|
|
B. Clinical characteristics of primary carnitine deficiency: a structured review using a case-by-case approach.
|
|
J Inherit Metab Dis.
|
|
2022;45:386-405.
|
|
[<a href="/pmc/articles/PMC9305179/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9305179</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34997761" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34997761</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.crefcoeur.2023.1177">Crefcoeur
|
|
L, Ferdinandusse
|
|
S, van der Crabben
|
|
SN, Dekkers
|
|
E, Fuchs
|
|
SA, Huidekoper
|
|
H, Janssen
|
|
M, Langendonk
|
|
J, Maase
|
|
R, de Sain
|
|
M, Rubio
|
|
E, van Spronsen
|
|
FJ, Vaz
|
|
FM, Verschoof
|
|
R, de Vries
|
|
M, Wijburg
|
|
F, Visser
|
|
G, Langeveld
|
|
M. Newborn screening for primary carnitine deficiency: who will benefit? - a retrospective cohort study.
|
|
J Med Genet.
|
|
2023;60:1177-85.
|
|
[<a href="/pmc/articles/PMC10715524/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10715524</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37487700" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37487700</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.elhattab.2010.19">El-Hattab
|
|
AW, Li
|
|
FY, Shen
|
|
J, Powell
|
|
BR, Bawle
|
|
EV, Adams
|
|
DJ, Wahl
|
|
E, Kobori
|
|
JA, Graham
|
|
B, Scaglia
|
|
F, Wong
|
|
LJ. Maternal primary carnitine deficiency uncovered by newborn screening: clinical, biochemical, and molecular aspects.
|
|
Genet Med.
|
|
2010;12:19-24.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/20027113" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20027113</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.elhattab.2015.107">El-Hattab
|
|
AW, Scaglia
|
|
F. Disorders of carnitine biosynthesis and transport.
|
|
Mol Genet Metab.
|
|
2015;116:107-12.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/26385306" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26385306</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.ferdinandusse.2019.1899">Ferdinandusse
|
|
S, Te Brinke
|
|
H, Ruiter
|
|
JPN, Haasjes
|
|
J, Oostheim
|
|
W, van Lenthe
|
|
H, IJlst
|
|
L, Ebberink
|
|
MS, Wanders
|
|
RJA, Vaz
|
|
FM, Waterham
|
|
HR. A mutation creating an upstream translation initiation codon in SLC22A5 5'UTR is a frequent cause of primary carnitine deficiency.
|
|
Hum Mutat.
|
|
2019;40:1899-904.
|
|
[<a href="/pmc/articles/PMC6790604/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6790604</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31187905" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31187905</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.frigeni.2017.1684">Frigeni
|
|
M, Balakrishnan
|
|
B, Yin
|
|
X, Calderon
|
|
FRO, Mao
|
|
R, Pasquali
|
|
M, Longo
|
|
N. Functional and molecular studies in primary carnitine deficiency.
|
|
Hum Mutat.
|
|
2017;38:1684-99.
|
|
[<a href="/pmc/articles/PMC5665702/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5665702</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28841266" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28841266</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.gallant.2017.76">Gallant
|
|
NM, Leydiker
|
|
K, Wilnai
|
|
Y, Lee
|
|
C, Lorey
|
|
F, Feuchtbaum
|
|
L, Tang
|
|
H, Carter
|
|
J, Enns
|
|
GM, Packman
|
|
S, Lin
|
|
HJ, Wilcox
|
|
WR, Cederbaum
|
|
SD, Abdenur
|
|
JE. Biochemical characteristics of newborns with carnitine transporter defect identified by newborn screening in California.
|
|
Mol Genet Metab.
|
|
2017;122:76-84.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28711408" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28711408</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.huang.2022.389">Huang
|
|
SJ, Amendola
|
|
LM, Sternen
|
|
DL. Variation among DNA banking consent forms: points for clinicians to bank on.
|
|
J Community Genet.
|
|
2022;13:389-97.
|
|
[<a href="/pmc/articles/PMC9314484/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9314484</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35834113" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35834113</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.ji.2023.1304458">Ji
|
|
X, Ge
|
|
Y, Ni
|
|
Q, Xu
|
|
S, Xiong
|
|
Z, Yang
|
|
L, Hu
|
|
L, Cao
|
|
Y, Lu
|
|
Y, Wei
|
|
Q, Kang
|
|
W, Zhuang
|
|
D, Zhou
|
|
W, Dong
|
|
X.
|
|
Primary carnitine deficiency: estimation of prevalence in Chinese population and insights into newborn screening.
|
|
Front Genet.
|
|
2023;14:1304458.
|
|
[<a href="/pmc/articles/PMC10730660/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10730660</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38125748" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 38125748</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.j_nsson.2017.519">Jónsson
|
|
H, Sulem
|
|
P, Kehr
|
|
B, Kristmundsdottir
|
|
S, Zink
|
|
F, Hjartarson
|
|
E, Hardarson
|
|
MT, Hjorleifsson
|
|
KE, Eggertsson
|
|
HP, Gudjonsson
|
|
SA, Ward
|
|
LD, Arnadottir
|
|
GA, Helgason
|
|
EA, Helgason
|
|
H, Gylfason
|
|
A, Jonasdottir
|
|
A, Jonasdottir
|
|
A, Rafnar
|
|
T, Frigge
|
|
M, Stacey
|
|
SN, Th Magnusson
|
|
O, Thorsteinsdottir
|
|
U, Masson
|
|
G, Kong
|
|
A, Halldorsson
|
|
BV, Helgason
|
|
A, Gudbjartsson
|
|
DF, Stefansson
|
|
K. Parental influence on human germline de novo mutations in 1,548 trios from Iceland.
|
|
Nature.
|
|
2017;549:519-22.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28959963" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28959963</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.koleske.2022.e2210247119">Koleske
|
|
ML, McInnes
|
|
G, Brown
|
|
JEH, Thomas
|
|
N, Hutchinson
|
|
K, Chin
|
|
MY, Koehl
|
|
A, Arkin
|
|
MR, Schlessinger
|
|
A, Gallagher
|
|
RC, Song
|
|
YS, Altman
|
|
RB, Giacomini
|
|
KM. Functional genomics of OCTN2 variants informs protein-specific variant effect predictor for carnitine transporter deficiency.
|
|
Proc Natl Acad Sci U S A.
|
|
2022;119:e2210247119.
|
|
[<a href="/pmc/articles/PMC9674959/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9674959</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36343260" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36343260</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.lee.2010.46">Lee
|
|
NC, Tang
|
|
NL, Chien
|
|
YH, Chen
|
|
CA, Lin
|
|
SJ, Chiu
|
|
PC, Huang
|
|
AC, Hwu
|
|
WL. Diagnoses of newborns and mothers with carnitine uptake defects through newborn screening.
|
|
Mol Genet Metab.
|
|
2010;100:46-50.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/20074989" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20074989</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.lef_vre.2023.6">Lefèvre
|
|
CR, Labarthe
|
|
F, Dufour
|
|
D, Moreau
|
|
C, Faoucher
|
|
M, Rollier
|
|
P, Arnoux
|
|
JB, Tardieu
|
|
M, Damaj
|
|
L, Bendavid
|
|
C, Dessein
|
|
AF, Acquaviva-Bourdain
|
|
C, Cheillan
|
|
D. Newborn screening of primary carnitine deficiency: an overview of worldwide practices and pitfalls to define an algorithm before expansion of newborn screening in France.
|
|
Int J Neonatal Screen.
|
|
2023;9:6.
|
|
[<a href="/pmc/articles/PMC9944086/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9944086</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36810318" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36810318</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.li.2010.e1632">Li
|
|
FY, El-Hattab
|
|
AW, Bawle
|
|
EV, Boles
|
|
RG, Schmitt
|
|
ES, Scaglia
|
|
F, Wong
|
|
LJ. Molecular spectrum of SLC22A5 (OCTN2) gene mutations detected in 143 subjects evaluated for systemic carnitine deficiency.
|
|
Hum Mutat.
|
|
2010;31:E1632-51.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/20574985" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20574985</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.lin.2021.503">Lin
|
|
Y, Lin
|
|
B, Chen
|
|
Y, Zheng
|
|
Z, Fu
|
|
Q, Lin
|
|
W, Zhang
|
|
W. Biochemical and genetic characteristics of patients with primary carnitine deficiency identified through newborn screening.
|
|
Orphanet J Rare Dis.
|
|
2021;16:503.
|
|
[<a href="/pmc/articles/PMC8642906/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8642906</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34863234" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34863234</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.lodewyckx.2023.107733">Lodewyckx
|
|
P, Issa
|
|
J, Gaschignard
|
|
M, Lamireau
|
|
D, De Lonlay
|
|
P, Servais
|
|
A, Barth
|
|
M, Courapied
|
|
S, Morin
|
|
G, Benbrik
|
|
N, Maillot
|
|
F, Babuty
|
|
D, Labarthe
|
|
F, Lefort
|
|
B.
|
|
Systemic primary carnitine deficiency induces severe arrhythmia due to shortening of QT interval.
|
|
Mol Genet Metab.
|
|
2023;140:107733.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/37979236" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37979236</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.longo.2006.77">Longo
|
|
N, Amat di San Filippo
|
|
C, Pasquali
|
|
M.
|
|
Disorders of carnitine transport and the carnitine cycle.
|
|
Am J Med Genet C Semin Med Genet.
|
|
2006;142C:77-85.
|
|
[<a href="/pmc/articles/PMC2557099/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2557099</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16602102" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16602102</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.longo.2016.2422">Longo
|
|
N, Frigeni
|
|
M, Pasquali
|
|
M. Carnitine transport and fatty acid oxidation.
|
|
Biochim Biophys Acta.
|
|
2016;1863:2422-35.
|
|
[<a href="/pmc/articles/PMC4967041/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4967041</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26828774" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26828774</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.onuki.2023.1341">Onuki
|
|
T, Hiroshima
|
|
S, Sawano
|
|
K, Shibata
|
|
N, Ogawa
|
|
Y, Nagasaki
|
|
K, Nyuzuki
|
|
H.
|
|
A study of maternal patients diagnosed with inborn errors of metabolism due to positive newborn mass screening in their newborns.
|
|
Children (Basel). 2023;10:1341.
|
|
[<a href="/pmc/articles/PMC10452974/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10452974</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37628339" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37628339</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.rose.2012.118">Rose
|
|
EC, di San Filippo
|
|
CA, Ndukwe Erlingsson
|
|
UC, Ardon
|
|
O, Pasquali
|
|
M, Longo
|
|
N. Genotype-phenotype correlation in primary carnitine deficiency.
|
|
Hum Mutat.
|
|
2012;33:118-23.
|
|
[<a href="/pmc/articles/PMC3240685/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3240685</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21922592" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21922592</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.rasmussen.2014.215">Rasmussen
|
|
J, Nielsen
|
|
OW, Janzen
|
|
N, Duno
|
|
M, Gislason
|
|
H, Køber
|
|
L, Steuerwald
|
|
U, Lund
|
|
AM. Carnitine levels in 26,462 individuals from the nationwide screening program for primary carnitine deficiency in the Faroe Islands.
|
|
J Inherit Metab Dis.
|
|
2014;37:215-22.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/23653224" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23653224</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.richards.2015.405">Richards
|
|
S, Aziz
|
|
N, Bale
|
|
S, Bick
|
|
D, Das
|
|
S, Gastier-Foster
|
|
J, Grody
|
|
WW, Hegde
|
|
M, Lyon
|
|
E, Spector
|
|
E, Voelkerding
|
|
K, Rehm
|
|
HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
|
|
Genet Med.
|
|
2015;17:405-24.
|
|
[<a href="/pmc/articles/PMC4544753/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4544753</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25741868" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25741868</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.schimmenti.2007.441">Schimmenti
|
|
LA, Crombez
|
|
EA, Schwahn
|
|
BC, Heese
|
|
BA, Wood
|
|
TC, Schroer
|
|
RJ, Bentler
|
|
K, Cederbaum
|
|
S, Sarafoglou
|
|
K, McCann
|
|
M, Rinaldo
|
|
P, Matern
|
|
D, di San Filippo
|
|
CA, Pasquali
|
|
M, Berry
|
|
SA, Longo
|
|
N. Expanded newborn screening identifies maternal primary carnitine deficiency.
|
|
Mol Genet Metab.
|
|
2007;90:441-5.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/17126586" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17126586</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.stenson.2020.1197">Stenson
|
|
PD, Mort
|
|
M, Ball
|
|
EV, Chapman
|
|
M, Evans
|
|
K, Azevedo
|
|
L, Hayden
|
|
M, Heywood
|
|
S, Millar
|
|
DS, Phillips
|
|
AD, Cooper
|
|
DN. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting.
|
|
Hum Genet.
|
|
2020;139:1197-207.
|
|
[<a href="/pmc/articles/PMC7497289/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7497289</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32596782" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32596782</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.van_den_heuvel.2023.134">van den Heuvel
|
|
LM, Kater-Kuipers
|
|
A, van Dijk
|
|
T, Crefcoeur
|
|
LL, Visser
|
|
G, Langeveld
|
|
M, Henneman
|
|
L. A qualitative study on the perspectives of mothers who had been diagnosed with primary carnitine deficiency through newborn screening of their child.
|
|
Orphanet J Rare Dis.
|
|
2023;18:134.
|
|
[<a href="/pmc/articles/PMC10236393/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10236393</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37268964" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37268964</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="cdsp.REF.wilson.2019.86">Wilson
|
|
C, Knoll
|
|
D, de Hora
|
|
M, Kyle
|
|
C, Glamuzina
|
|
E, Webster
|
|
D. The decision to discontinue screening for carnitine uptake disorder in New Zealand.
|
|
J Inherit Metab Dis.
|
|
2019;42:86-92.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/30740730" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30740730</span></a>]</div></p></li></ul></div></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK84551_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">Ayman W El-Hattab</span>, MD, FAAP, FACMG<div class="affiliation small">Professor, Department of Clinical Sciences<br />College of Medicine<br />University of Sharjah<br />Sharjah, United Arab Emirates<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.oohay@wabattahle" class="oemail">moc.oohay@wabattahle</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Mohammed Almannai</span>, MD, FAAP, FACMG<div class="affiliation small">Genetics and Precision Medicine department (GPM)<br />King Abdullah Specialized Children's Hospital (KASCH)<br />King Abdulaziz Medical City<br />Ministry of National Guard Health Affairs (MNG-HA)<br />Riyadh, Saudi Arabia<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.liamg@18iannamm" class="oemail">moc.liamg@18iannamm</a></div></div></div><h3>Publication History</h3><p class="small">Initial Posting: <span itemprop="datePublished">March 15, 2012</span>; Last Update: <span itemprop="dateModified">December 5, 2024</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2025, University of Washington, Seattle. GeneReviews is
|
|
a registered trademark of the University of Washington, Seattle. All rights
|
|
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
|
|
hereby granted to reproduce, distribute, and translate copies of content materials for
|
|
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2025 University of
|
|
Washington) are included with each copy; (ii) a link to the original material is provided
|
|
whenever the material is published elsewhere on the Web; and (iii) reproducers,
|
|
distributors, and/or translators comply with the <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/GRcopyright_permiss/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">GeneReviews® Copyright Notice and Usage
|
|
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
|
|
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
|
|
use.</p><p class="small">For more information, see the <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/GRcopyright_permiss/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">GeneReviews® Copyright Notice and Usage
|
|
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
|
|
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div></div><h3>Publisher</h3><p><a href="http://www.washington.edu" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">University of Washington, Seattle</a>, Seattle (WA)</p><h3>NLM Citation</h3><p>El-Hattab AW, Almannai M. Primary Carnitine Deficiency. 2012 Mar 15 [Updated 2024 Dec 5]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/gene/microcephaly/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/gene/pcd/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobcdspTprimarycarnitinedeficiencytest"><div id="cdsp.T.primary_carnitine_deficiency_test" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Primary Carnitine Deficiency: Testing Recommended at the Time of Diagnosis of Low Carnitine Blood Levels via NBS</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_test/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdsp.T.primary_carnitine_deficiency_test_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cdsp.T.primary_carnitine_deficiency_test_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Laboratory Test</th><th id="hd_h_cdsp.T.primary_carnitine_deficiency_test_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Results</th><th id="hd_h_cdsp.T.primary_carnitine_deficiency_test_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_test_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Free & total blood & urine carnitine concentrations <sup>1</sup></b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_test_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Extremely reduced plasma free, acylated, & total (i.e., the sum of free & acylated) carnitine concentrations (i.e., <10% of controls) are highly suggestive of PCD.</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_test_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plasma carnitine concentrations should be measured in all mothers of infants found to have low free carnitine levels on NBS to determine if the mother &/or infant have PCD.</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_test_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Plasma acylcarnitine profile</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_test_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Infants w/PCD have low plasma concentration of all acylcarnitines & therefore plasma acylcarnitine profile may not be successful. If a profile can be generated, there is typically no specific elevation of any acylcarnitine species.</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_test_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Useful to rule out other causes of low free carnitine concentrations, incl organic acidemias & defects of fatty acid oxidation (See <a href="#cdsp.Differential_Diagnosis">Differential Diagnosis</a>.)</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_test_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Urine organic acid analysis</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_test_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nondiagnostic for PCD</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_test_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Useful to rule out other causes of low carnitine levels, incl organic acidemias & defects of fatty acid oxidation (See <a href="#cdsp.Differential_Diagnosis">Differential Diagnosis</a>.)</div></li><li class="half_rhythm"><div>Note: Nonspecific dicarboxylic aciduria occurs in some persons w/PCD & is common in fatty acid oxidation disorders w/acute decompensation.</div></li></ul>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PCD = primary carnitine deficiency</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="cdsp.TF.1.1"><p class="no_margin">See ACMG <a href="https://www.acmg.net/PDFLibrary/C0-Algorithm.pdf" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">C0 Algorithm</a> (pdf). Because increased concentrations of these metabolites individually are not entirely specific to primary carnitine deficiency (PCD), follow-up testing is required to establish or rule out the diagnosis of PCD (see <a href="#cdsp.Establishing_the_Diagnosis">Establishing the Diagnosis</a>). Measurement of blood glucose, electrolytes, blood gas, ammonia, liver transaminases, and creatine kinase may be performed to assess disease severity.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobcdspTmoleculargenetictestingusedin"><div id="cdsp.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Primary Carnitine Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK84551/table/cdsp.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdsp.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cdsp.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene <sup>1</sup></th><th id="hd_h_cdsp.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_cdsp.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants <sup>2</sup> Identified by Method</th></tr></thead><tbody><tr><td headers="hd_h_cdsp.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>SLC22A5</i>
|
|
</td><td headers="hd_h_cdsp.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis <sup>3</sup></td><td headers="hd_h_cdsp.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~95% <sup>4, 5</sup></td></tr><tr><td headers="hd_h_cdsp.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted deletion/duplication analysis <sup>6</sup></td><td headers="hd_h_cdsp.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~5% <sup>4</sup></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="cdsp.TF.2.1"><p class="no_margin">See <a href="/books/NBK84551/?report=reader#cdsp.molgen.TA">Table A. Genes and Databases</a> for chromosome locus and protein.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="cdsp.TF.2.2"><p class="no_margin">See <a href="#cdsp.Molecular_Genetics">Molecular Genetics</a> for information on variants detected in this gene.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="cdsp.TF.2.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include missense, nonsense, and splice site variants and small intragenic deletions/insertions; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <a href="/books/n/gene/app2/?report=reader">here</a>.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4. </dt><dd><div id="cdsp.TF.2.4"><p class="no_margin"><a class="bibr" href="#cdsp.REF.frigeni.2017.1684" rid="cdsp.REF.frigeni.2017.1684">Frigeni et al [2017]</a> and data derived from the subscription-based professional view of Human Gene Mutation Database [<a class="bibr" href="#cdsp.REF.stenson.2020.1197" rid="cdsp.REF.stenson.2020.1197">Stenson et al 2020</a>]</p></div></dd></dl><dl class="bkr_refwrap"><dt>5. </dt><dd><div id="cdsp.TF.2.5"><p class="no_margin">Sequence analysis should include analysis of <i>SLC22A5</i> 5′ untranslated region (UTR). In a cohort of 236 individuals, pathogenic variant c.-149G>A in the 5′ UTR accounted for 14% of pathogenic variants [<a class="bibr" href="#cdsp.REF.ferdinandusse.2019.1899" rid="cdsp.REF.ferdinandusse.2019.1899">Ferdinandusse et al 2019</a>].</p></div></dd></dl><dl class="bkr_refwrap"><dt>6. </dt><dd><div id="cdsp.TF.2.6"><p class="no_margin">Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include a range of techniques such as quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications. Exome and genome sequencing may be able to detect deletions/duplications using breakpoint detection or read depth; however, sensitivity can be lower than gene-targeted deletion/duplication analysis.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobcdspTprimarycarnitinedeficiencysele"><div id="cdsp.T.primary_carnitine_deficiency_sele" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Primary Carnitine Deficiency: Select Features</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_sele/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdsp.T.primary_carnitine_deficiency_sele_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_1" style="text-align:left;vertical-align:middle;">Feature</th><th id="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_2" style="text-align:left;vertical-align:middle;">Infantile Early Diagnosis & Treatment</th><th id="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Untreated Symptomatic Individual</th></tr><tr><th headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3" id="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Infantile onset</th><th headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3" id="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Childhood onset</th><th headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3" id="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Adult onset</th></tr></thead><tbody><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Typical age at presentation/onset</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Newborn</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3 hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3 mos-2 yrs</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3 hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2-4 yrs</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3 hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Adulthood</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Metabolic decompensation <sup>1</sup></b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_2" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;">Rare w/appropriate treatment</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3 hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3 hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3 hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">±</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Hepatomegaly</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3 hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_1" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3 hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3 hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Cardio(myo)pathy</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3 hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_1" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">±</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3 hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3 hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">±</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Neurologic manifestations</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3 hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_1" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3 hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_1_3 hd_h_cdsp.T.primary_carnitine_deficiency_sele_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">±</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Based on <a class="bibr" href="#cdsp.REF.elhattab.2015.107" rid="cdsp.REF.elhattab.2015.107">El-Hattab & Scaglia [2015]</a>, <a class="bibr" href="#cdsp.REF.longo.2016.2422" rid="cdsp.REF.longo.2016.2422">Longo et al [2016]</a>, <a class="bibr" href="#cdsp.REF.crefcoeur.2022.386" rid="cdsp.REF.crefcoeur.2022.386">Crefcoeur et al [2022]</a></p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="cdsp.TF.3.1"><p class="no_margin">Hypoketotic hypoglycemia, hyperammonemia, elevated liver enzymes</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobcdspTselectedautosomalrecessivediso"><div id="cdsp.T.selected_autosomal_recessive_diso" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Selected Autosomal Recessive Disorders Associated with Secondary Carnitine Deficiency in the Differential Diagnosis of Primary Carnitine Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK84551/table/cdsp.T.selected_autosomal_recessive_diso/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdsp.T.selected_autosomal_recessive_diso_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Biochemical Phenotype</th></tr></thead><tbody><tr><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>ACADM</i>
|
|
</td><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/mcad/?report=reader">Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency</a>
|
|
</td><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elevated C8, C10, C10:1; increased excretion of dicarboxylic acids</td></tr><tr><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>ACADS</i>
|
|
</td><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/scad/?report=reader">Short-chain acyl-CoA dehydrogenase (SCAD) deficiency</a>
|
|
</td><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Elevated C4; increased excretion of ethylmalonic acid & dicarboxylic acids</td></tr><tr><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>ACADVL</i>
|
|
</td><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/vlcad/?report=reader">Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency</a>
|
|
</td><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Elevated C14:1, C14:2, C14, C12:1; increased excretion of dicarboxylic acids</td></tr><tr><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>CPT2</i>
|
|
</td><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/cpt2/?report=reader">Carnitine palmitoyltransferase II deficiency</a>
|
|
</td><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Elevated C16, C18:1; increased excretion of dicarboxylic acids</td></tr><tr><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>HADHA</i>
|
|
<br />
|
|
<i>HADHB</i>
|
|
</td><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/lchad/?report=reader">Long-chain hydroxyacyl-CoA dehydrogenase (VCHAD) deficiency / trifunctional protein deficiency</a>
|
|
</td><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Elevated C16-OH, C18-OH, C18:1-OH; increased excretion of 3-hydroxy-dicarboxylic acids</td></tr><tr><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>SLC25A20</i>
|
|
</td><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/cact-def/?report=reader">Carnitine-acylcarnitine translocase deficiency</a>
|
|
</td><td headers="hd_h_cdsp.T.selected_autosomal_recessive_diso_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Elevated C16, C18:1; increased excretion of dicarboxylic acids</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">AR = autosomal recessive; CoA = coenzyme A; MOI = mode of inheritance</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobcdspTprimarycarnitinedeficiencyreco"><div id="cdsp.T.primary_carnitine_deficiency_reco" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Primary Carnitine Deficiency: Recommended Evaluations Following Initial Diagnosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_reco/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdsp.T.primary_carnitine_deficiency_reco_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Consultation w/metabolic physician / biochemical geneticist</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Transfer to specialist center w/experience in mgmt of inherited metabolic diseases (strongly recommended)</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Cardiology</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Echocardiogram & electrocardiogram</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Laboratory tests</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>CK & liver transaminases</div></li><li class="half_rhythm"><div>Post-prandial blood glucose concentration</div></li><li class="half_rhythm"><div>Plasma free/total carnitine concentration following initiation of treatment</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Consultation w/psychologist &/or social worker</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To ensure understanding of diagnosis & assess parental / affected person's coping skills & <a href="#cdsp.Resources">resources</a> as needed</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Genetic counseling by genetics professionals <sup>1</sup></b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To obtain a pedigree & inform affected persons & their families re nature, MOI, & implications of PCD to facilitate medical & personal decision making</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CK = creatine kinase; MOI = mode of inheritance; PCD = primary carnitine deficiency</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="cdsp.TF.5.1"><p class="no_margin">Medical geneticist, certified genetic counselor, certified advanced genetic nurse</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobcdspTprimarycarnitinedeficiencytarg"><div id="cdsp.T.primary_carnitine_deficiency_targ" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Primary Carnitine Deficiency: Targeted Therapy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_targ/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdsp.T.primary_carnitine_deficiency_targ_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cdsp.T.primary_carnitine_deficiency_targ_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_cdsp.T.primary_carnitine_deficiency_targ_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dosage</th><th id="hd_h_cdsp.T.primary_carnitine_deficiency_targ_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_targ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Oral levocarnitine supplementation</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_targ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100-200 mg/kg/day divided 3x/day <sup>1</sup></td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_targ_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">The weight-based carnitine dose needs to be adjusted according to plasma carnitine concentrations, which should be measured frequently.</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="cdsp.TF.6.1"><p class="no_margin">High doses of oral levocarnitine can cause increased gastrointestinal motility, diarrhea, and intestinal discomfort. Oral levocarnitine can be metabolized by intestinal bacteria to produce trimethylamine, which has a fishy odor. Oral metronidazole at a dose of 10 mg/kg/day for 7-10 days and/or decreasing the carnitine dose usually results in the resolution of the odor [<a class="bibr" href="#cdsp.REF.longo.2016.2422" rid="cdsp.REF.longo.2016.2422">Longo et al 2016</a>].</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobcdspTprimarycarnitinedeficiencyrout"><div id="cdsp.T.primary_carnitine_deficiency_rout" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p>Primary Carnitine Deficiency: Routine Outpatient Treatment of Manifestations</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_rout/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdsp.T.primary_carnitine_deficiency_rout_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cdsp.T.primary_carnitine_deficiency_rout_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Principal Concern</th><th id="hd_h_cdsp.T.primary_carnitine_deficiency_rout_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_cdsp.T.primary_carnitine_deficiency_rout_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_rout_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Prevent carnitine deficiency by maintaining normal blood carnitine concentration</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_rout_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Oral levocarnitine (See <a href="#cdsp.Targeted_Therapy">Targeted Therapy</a>.)</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_rout_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_rout_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Prevent hypoglycemia</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_rout_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To reduce risk of metabolic, hepatic, cardiac, & muscular complications:
|
|
<ul><li class="half_rhythm"><div>Frequent feeds</div></li><li class="half_rhythm"><div>Avoid fasting</div></li></ul>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_rout_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Written protocols for outpatient routine & emergency treatment should be provided to parents, primary care providers, teachers, & school staff. <sup>1, 2</sup></div></li><li class="half_rhythm"><div>Emergency letter/card should be provided summarizing key info, principles of emergency treatment, & contact information for primary treating metabolic center.</div></li><li class="half_rhythm"><div>For any planned travel or vacations, consider contacting center of expertise near destination prior to travel dates.</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_rout_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Prevent complications during surgery or procedure (incl dental procedures)</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_rout_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Notify designated metabolic center in advance of procedure to discuss perioperative mgmt w/surgeons & anesthesiologists. <sup>1, 2</sup></div></li><li class="half_rhythm"><div>Hospitalization to administer IV glucose is recommended for persons w/PCD who are required to fast because of medical or surgical procedures or who cannot tolerate oral intake because of illness such as gastroenteritis.</div></li></ul>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_rout_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Consider placing a "flag" in affected person's medical record such that all care providers are aware of diagnosis & need to solicit opinions & guidance from designated metabolic specialists in the setting of certain procedures.</div></li><li class="half_rhythm"><div>Emergency surgeries/procedures require planning input from physicians w/expertise in inherited metabolic diseases (w/respect to perioperative fluid & nutritional mgmt).</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_rout_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Consider transition from pediatric to adult-centered multidisciplinary care, depending on age</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_rout_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">As a lifelong disorder w/varying implications according to age, a smooth transition of care from pediatric setting to adult setting for long-term mgmt is ideal. <sup>3, 4</sup></td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_rout_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unfortunately, standardized procedures for transitional care do not exist for PCD due to the absence of multidisciplinary outpatient departments.</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">IV = intravenous; PCD = primary carnitine deficiency</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="cdsp.TF.7.1"><p class="no_margin">Essential information including written treatment protocols should be provided <i>before</i> inpatient emergency treatment might be necessary.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="cdsp.TF.7.2"><p class="no_margin">Perioperative/perianesthetic management precautions may include evaluation at specialist anesthetic clinics for affected individuals deemed to be high risk for perioperative complications. Note: Hospitalization to administer IV glucose is recommended for individuals with PCD who are required to fast because of medical or surgical procedures or who cannot tolerate oral intake because of an illness such as gastroenteritis.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="cdsp.TF.7.3"><p class="no_margin">Transitional care concepts have been developed in which adult internal medicine specialists initially see individuals with PCD together with pediatric metabolic experts, dietitians, psychologists, and social workers.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4. </dt><dd><div id="cdsp.TF.7.4"><p class="no_margin">As the long-term course of pediatric metabolic diseases in this age group is not yet fully characterized, continuous supervision by a center of expertise with metabolic diseases with sufficient resources is essential.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobcdspTprimarycarnitinedeficiencyemer"><div id="cdsp.T.primary_carnitine_deficiency_emer" class="table"><h3><span class="label">Table 8. </span></h3><div class="caption"><p>Primary Carnitine Deficiency: Emergency Outpatient Treatment</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_emer/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdsp.T.primary_carnitine_deficiency_emer_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cdsp.T.primary_carnitine_deficiency_emer_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Indication</th><th id="hd_h_cdsp.T.primary_carnitine_deficiency_emer_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_cdsp.T.primary_carnitine_deficiency_emer_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consideration/Other</th></tr></thead><tbody><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_emer_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Catabolism caused by infection, fever, vomiting, or diarrhea</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_emer_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>If affected person is not vomiting, carnitine & feeds may be given orally.</div></li><li class="half_rhythm"><div>Carbohydrate supplementation orally or via tube feeding <sup>1</sup></div></li><li class="half_rhythm"><div>Increase carnitine supplementation.</div></li><li class="half_rhythm"><div>Assess serum CK concentration & liver transaminases during acute illness.</div></li></ul>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_emer_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Trial of outpatient treatment at home for up to 12 hrs</div></li><li class="half_rhythm"><div>Reassessment (~every 2 hrs) for clinical changes <sup>2</sup></div></li><li class="half_rhythm"><div>Hospitalization to administer IV glucose is recommended for persons w/PCD who cannot tolerate oral intake because of vomiting.</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_emer_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Fever</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_emer_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Administration of antipyretics (acetaminophen, ibuprofen)</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_emer_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_emer_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Occasional vomiting</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_emer_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Antiemetics <sup>3</sup></td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_emer_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Based on <a href="https://bimdg.org.uk/site/index.asp" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">British Inherited Metabolic Diseases Group</a> emergency management recommendations for PCD</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CK = creatine kinase; IV = intravenous; PCD = primary carnitine deficiency</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="cdsp.TF.8.1"><p class="no_margin">Stringent guidelines to quantify carbohydrate/caloric requirements are available to guide dietary recommendations in the outpatient setting, with some centers recommending frequent provision of carbohydrate-rich, protein-free beverages every two hours, with frequent reassessment.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="cdsp.TF.8.2"><p class="no_margin">Alterations in mentation/alertness, fever, and enteral feeding tolerance, with any new or evolving clinical features discussed with the designated center of expertise for inherited metabolic diseases</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="cdsp.TF.8.3"><p class="no_margin">Some classes of antiemetics can be used safely on an occasional basis to temporarily improve enteral tolerance of food and beverages at home or during transfer to hospital.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobcdspTprimarycarnitinedeficiencyacut"><div id="cdsp.T.primary_carnitine_deficiency_acut" class="table"><h3><span class="label">Table 9. </span></h3><div class="caption"><p>Primary Carnitine Deficiency: Acute Inpatient Treatment</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_acut/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdsp.T.primary_carnitine_deficiency_acut_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Indication</th><th id="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consideration/Other</th></tr></thead><tbody><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Increased catabolism (due to fever, perioperative/peri-interventional fasting periods, repeated vomiting/diarrhea), hypoglycemia</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Administration of high-calorie fluids &, if needed, insulin</div></li><li class="half_rhythm"><div>Levocarnitine supplementation (100 mg/kg divided q.i.d. PO or IV)</div></li></ul>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Clinical myalgia, muscle tenderness, &/or urinary discoloration</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Administration of high-energy fluids &, if needed, insulin</div></li><li class="half_rhythm"><div>Levocarnitine supplementation (100 mg/kg divided q.i.d. PO or IV)</div></li></ul>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plasma CK &/or urinalysis may be indicated for assessment of rhabdomyolysis.</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>New or evolving neurologic symptoms (e.g., muscular hypotonia, irritability, rigors, dystonia, reduced consciousness)</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Administration of high-energy fluids &, if needed, insulin</div></li><li class="half_rhythm"><div>Levocarnitine supplementation (100 mg/kg divided q.i.d. PO or IV)</div></li></ul>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Hepatic involvement</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Administration of high-energy fluids &, if needed, insulin</div></li><li class="half_rhythm"><div>Levocarnitine supplementation (100 mg/kg divided q.i.d. PO or IV)</div></li></ul>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor for evidence of liver damage (measurement of liver transaminases)</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Cardiomyopathy</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Eval by cardiologist</div></li><li class="half_rhythm"><div>EKG</div></li><li class="half_rhythm"><div>Echocardiogram</div></li></ul>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_acut_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">CK = creatine kinase; IV = intravenous; PO = <i>per os</i> (orally); q.i.d = four times a day</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobcdspTprimarycarnitinedeficiencyreco1"><div id="cdsp.T.primary_carnitine_deficiency_reco_1" class="table"><h3><span class="label">Table 10. </span></h3><div class="caption"><p>Primary Carnitine Deficiency: Recommended Surveillance</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK84551/table/cdsp.T.primary_carnitine_deficiency_reco_1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdsp.T.primary_carnitine_deficiency_reco_1_lrgtbl__"><table><thead><tr><th id="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Concern</th><th id="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Carnitine deficiency</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Measurement of plasma free/total carnitine by experienced metabolic physician w/adjustments in carnitine supplementation based on age, weight, & diet</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequently until levels reach normal range; then every 4 mos during infancy & early childhood, every 6 mos in older children, & annually in adults</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Growth</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Measurement of height, weight, & head circumference</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At each visit throughout childhood, esp if poorly treated or untreated</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Development</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assessment of developmental milestones</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At each visit throughout childhood</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Cognition</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neuropsychological testing using age-appropriate standardized assessment testing</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">As needed</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Quality of life</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess quality of life using standard questioning or specific assessment tools for affected persons & parents/caregivers</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Cardiac</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>EKG</div></li><li class="half_rhythm"><div>Echocardiogram</div></li></ul>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Annually during childhood; less frequently in adulthood</div></li><li class="half_rhythm"><div>Note: In those nonadherent w/carnitine supplementation, consider more frequent monitoring.</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Family/Community</b>
|
|
</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources), care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning).</td><td headers="hd_h_cdsp.T.primary_carnitine_deficiency_reco_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At each visit</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobcdspmolgenTA"><div id="cdsp.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Primary Carnitine Deficiency: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK84551/table/cdsp.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdsp.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_cdsp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_cdsp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_cdsp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_cdsp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_cdsp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_cdsp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_cdsp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/6584" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>SLC22A5</i>
|
|
</a>
|
|
</td><td headers="hd_b_cdsp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=6584" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">5q31<wbr style="display:inline-block"></wbr>​.1</a>
|
|
</td><td headers="hd_b_cdsp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/O76082" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Organic cation/carnitine transporter 2</a>
|
|
</td><td headers="hd_b_cdsp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://databases.lovd.nl/shared/genes/SLC22A5" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">SLC22A5 database</a>
|
|
</td><td headers="hd_b_cdsp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SLC22A5" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">SLC22A5</a>
|
|
</td><td headers="hd_b_cdsp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SLC22A5[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">SLC22A5</a>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div id="cdsp.TFA.1"><p class="no_margin">Data are compiled from the following standard references: gene from
|
|
<a href="http://www.genenames.org/index.html" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">HGNC</a>;
|
|
chromosome locus from
|
|
<a href="http://www.omim.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">OMIM</a>;
|
|
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">UniProt</a>.
|
|
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
|
|
<a href="/books/n/gene/app1/?report=reader">here</a>.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobcdspmolgenTB"><div id="cdsp.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Primary Carnitine Deficiency (<a href="/omim/212140,603377" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK84551/table/cdsp.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdsp.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/212140" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">212140</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CARNITINE DEFICIENCY, SYSTEMIC PRIMARY; CDSP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/603377" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">603377</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 5; SLC22A5</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobcdspTslc22a5pathogenicvariantsrefer"><div id="cdsp.T.slc22a5_pathogenic_variants_refer" class="table"><h3><span class="label">Table 11. </span></h3><div class="caption"><p><i>SLC22A5</i> Pathogenic Variants Referenced in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK84551/table/cdsp.T.slc22a5_pathogenic_variants_refer/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cdsp.T.slc22a5_pathogenic_variants_refer_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cdsp.T.slc22a5_pathogenic_variants_refer_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th><th id="hd_h_cdsp.T.slc22a5_pathogenic_variants_refer_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_cdsp.T.slc22a5_pathogenic_variants_refer_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_cdsp.T.slc22a5_pathogenic_variants_refer_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment [Reference]</th></tr></thead><tbody><tr><td headers="hd_h_cdsp.T.slc22a5_pathogenic_variants_refer_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_003060.4" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NM_003060<wbr style="display:inline-block"></wbr>​.4</a>
|
|
</td><td headers="hd_h_cdsp.T.slc22a5_pathogenic_variants_refer_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-149G>A</td><td headers="hd_h_cdsp.T.slc22a5_pathogenic_variants_refer_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_cdsp.T.slc22a5_pathogenic_variants_refer_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pathogenic variant in the 5' UTR [<a class="bibr" href="#cdsp.REF.ferdinandusse.2019.1899" rid="cdsp.REF.ferdinandusse.2019.1899">Ferdinandusse et al 2019</a>]</td></tr><tr><td headers="hd_h_cdsp.T.slc22a5_pathogenic_variants_refer_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_003060.4" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NM_003060<wbr style="display:inline-block"></wbr>​.4</a>
|
|
<br />
|
|
<a href="https://www.ncbi.nlm.nih.gov/protein/NP_003051.1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NP_003051<wbr style="display:inline-block"></wbr>​.1</a>
|
|
</td><td headers="hd_h_cdsp.T.slc22a5_pathogenic_variants_refer_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.95A>G</td><td headers="hd_h_cdsp.T.slc22a5_pathogenic_variants_refer_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn32Ser</td><td headers="hd_h_cdsp.T.slc22a5_pathogenic_variants_refer_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Founder pathogenic variant in the Faroe Islands [<a class="bibr" href="#cdsp.REF.rasmussen.2014.215" rid="cdsp.REF.rasmussen.2014.215">Rasmussen et al 2014</a>]</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">UTR = untranslated region</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="https://varnomen.hgvs.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/?report=reader">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></dl></div></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script><script type="text/javascript">if (typeof (jQuery) != 'undefined') { (function ($) { $(function () { var min = Math.ceil(1); var max = Math.floor(100000); var randomNum = Math.floor(Math.random() * (max - min)) + min; var surveyUrl = "/projects/Gene/portal/surveys/seqdbui-survey.js?rando=" + randomNum.toString(); $.getScript(surveyUrl, function () { try { ncbi.seqDbUISurvey.init(); } catch (err) { console.info(err); } }).fail(function (jqxhr, settings, exception) { console.info('Cannot load survey script', jqxhr); });; }); })(jQuery); };</script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|